Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.90 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502039 | 0.94 | HTR4 (1.00) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL29397805 | 0.94 | HTR4 (1.00) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Maleic Acid SCHEMBL2942174 | 0.90 | HTR4 (0.90) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7293994 | 0.89 | HTR4 (0.89) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7300971 | 0.85 | HTR4 (0.81) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Maleic Acid SCHEMBL7295111 | 0.84 | HTR4 (0.81) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Fumaric Acid SCHEMBL7295114 | 0.84 | HTR4 (0.81) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7300888 | 0.82 | HTR4 (0.77) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7291228 | 0.81 | HTR4 (0.76) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7294699 | 0.81 | HTR4 (0.76) | HTR4CYP2C9PMP22NPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250228860-A1 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | SUPERNUS PHARMACEUTICALS, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250009752-A1 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | SUPERNUS PHARMACEUTICALS INC (US) | 2025-01-09 | — | — | US | disclosed |
| US-12121523-B2 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | SUPERNUS PHARMACEUTICALS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240132451-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3337486-B1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11845722-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230102784-A1 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11458143-B2 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | SUPERNUS PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220233548-A1 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) | SUPERNUS PHARMACEUTICALS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| US-11324753-B2 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) | SUPERNUS PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | HTR4 1023/4885CYP2C9 73/4885PMP22 2635/4885 |
| US-11845722-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR4 470/4885CYP2C9 2040/4885PMP22 582/4885 |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR4 470/4885CYP2C9 2040/4885PMP22 582/4885 |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR4 470/4885CYP2C9 2040/4885PMP22 582/4885 |
| US-11459300-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | HTR4 470/4885CYP2C9 2040/4885PMP22 582/4885 |
| US-20240132451-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | HTR4 470/4885CYP2C9 2040/4885PMP22 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.